CoChat

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial

Open access
Khanna, Dinesh, Spino, Cathie, Johnson, Sindhu, Chung, Lorinda, Whitfield, Michael L., Denton, Christopher P., Berrocal, Veronica, Franks, Jennifer, Mehta, Bhavan, Molitor, Jerry, Steen, Virginia D., Lafyatis, Robert, Simms, Robert W., Gill, Anna, Kafaja, Suzanne, Frech, Tracy M., Hsu, Vivien, Domsic, Robyn T., Pope, Janet E., Gordon, Jessica K., Mayes, Maureen D., Schiopu, Elena, Young, Amber, Sandorfi, Nora, Park, Jane, Hant, Faye N., Bernstein, Elana J., Chatterjee, Soumya, Castelino, Flavia V., Ajam, Ali, Wang, Yue, Wood, Tammara, Allanore, Yannick, Matucci‐Cerinic, Marco, Distler, Oliver, Singer, Ora, Bush, Erica, Fox, David A., Furst, Daniel E. · 2020 · Arthritis & Rheumatology
Cited by 225

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Objective: T cells play a key role in the pathogenesis of early systemic sclerosis. This study was undertaken to assess the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dc SS c). Methods: In this 12‐month, randomized, double‐blind, placebo‐controlled trial, participants were randomized 1:1 to receive either subcutaneous abatacept 125 mg or matching placebo, stratified by duration of dc SS c. Escape therapy was allowed at 6 months for worsening disease. The coprimary end points were change in the modified Rodnan skin thickness score ( MRSS ) compared to baseline and safety over 12 months. Differences in longitudinal outcomes were assessed according to treatment using linear mixed models, with outcomes censored after initiation of escape therapy. Skin tissue obtained from participants at baseline was classified into intrinsic gene expression subsets. Results: Among 88 participants, the adjusted mean change in the MRSS at 12 months was −6.24 units for those receiving abatacept and −4.49 units for those receiving placebo, with an adjusted mean treatment difference of −1.75 units ( P = 0.28). Outcomes for 2 secondary measures (Health Assessment Questionnaire disability index and a composite measure) were clinically and statistically significantly better with abatacept. The proportion of subjects in whom escape therapy was needed was higher in the placebo group relative to the abatacept group (36% versus 16%). In the inflammatory and normal‐like skin gene expression subsets, decline in the MRSS over 12 months was clinically and significantly greater in the abatacept group versus the placebo group ( P < 0.001 and P = 0.03, respectively). In the abatacept group, adverse events occurred in 35 participants versus 40 participants in the placebo group, including 2 deaths and 1 death, respectively. Conclusion: In this phase II trial, abatacept was well‐tolerated, but change in the MRSS was not statistically significant. Secondary outcome measures, including gene expression subsets, showed evidence in support of abatacept. These data should be confirmed in a phase III trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.41055

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 225

Metadata

Authors
Khanna, D., Spino, C., Johnson, S., Chung, L., Whitfield, M. L., Denton, C. P., Berrocal, V., Franks, J., Mehta, B., Molitor, J., Steen, V. D., Lafyatis, R., Simms, R. W., Gill, A., Kafaja, S., Frech, T. M., Hsu, V., Domsic, R. T., Pope, J. E., Gordon, J. K., Mayes, M. D., Schiopu, E., Young, A., Sandorfi, N., Park, J., Hant, F. N., Bernstein, E. J., Chatterjee, S., Castelino, F. V., Ajam, A., Wang, Y., Wood, T., Allanore, Y., Matucci‐Cerinic, M., Distler, O., Singer, O., Bush, E., Fox, D. A., & Furst, D. E.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2019-12-10
Volume
72
Issue
1
Pages
125-136
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2963254827
Cited by
225
References
3
FWCI
21.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.